Glycomics or Glycobiology Market Report 2026

Glycomics or Glycobiology Market Overview

• Glycomics or Glycobiology market size has reached to $2.13 billion in 2025 • Expected to grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 17% • Growth Driver: The Surge In Pharmaceutical Product Demand Fuels Growth Of The Glycomics Or Glycobiology Market • Market Trend: Innovative Platforms Transform Carbohydrate-Based Therapeutic And Vaccine Discovery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glycomics or Glycobiology Market?

Glycomics, or glycobiology, refers to the study of the structure, biosynthesis, and biology of saccharides (including sugar chains or glycans) that are widely distributed in nature. Glycans are researched in glycobiology for their structure, production, and biology. The major products of glycomics or glycobiology are enzymes, kits, reagents and chemicals, instruments, and carbohydrates. Enzymes refer to biological polymers that catalyze biochemical reactions. These are used in various applications such as drug discovery and development, disease diagnostics, and others, and these are used in academic research institutes, pharmaceutical, and biotechnology companies and clinical laboratories.

What Is The Glycomics or Glycobiology Market Growth Forecast?

The glycomics or glycobiology market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to precision medicine expansion, pharmaceutical R&D investments, demand for biomarker discovery, technological advances in mass spectrometry, increased translational research. Major trends in the forecast period include expansion of glycan-based biological research, increased use of glycomics in drug discovery, growing demand for advanced glycan analysis tools, rising integration of glycobiology in diagnostics, increased academic and industrial collaborations.

What Is The Driver Of The Glycomics or Glycobiology Market?

Increasing demand for pharmaceutical products is expected to propel the growth of the glycomics or glycobiology market going forward. Pharmaceutical products refer to medications or drugs that are specifically formulated to diagnose, prevent, treat, or cure diseases or medical conditions in humans or animals. glycomics and glycobiology are integral to pharmaceutical development, providing insights into disease mechanisms, identifying therapeutic targets, and optimizing the design and efficacy of drugs for a wide range of medical conditions. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions.Therefore, increasing demand for pharmaceutical products is driving the growth of the glycomics or glycobiology industry.

Key Players In The Global Glycomics or Glycobiology Market

Major companies operating in the glycomics or glycobiology market are Aligent Technologies Inc., Bruker Corporation, Merck Co. & KgaA, New England Biolabs Inc., Danaher Corporation, Shimadzu Corporation, ProZyme Inc., Takara Bio Inc., Asparia Glycomics SL, Lectenz Bio, Chemily Glycoscience LLC, Z Biotech LLC, RayBiotech Inc., Thermo Fisher Scientific Inc., Promega Corporation, Bio-Techne Corp., AMS Bio LLC, Ludger Ltd., CD BioGlyco Ltd., GlycoDiag SAS, Kode Biotech Limited, Glyxera GmBH, Glycomix Ltd., R&D Systems Inc.

Global Glycomics or Glycobiology Market Trends and Insights

Major companies operating in the glycobiology market are focusing on developing innovative solutions, such as glycan‑display platforms, to accelerate the discovery of carbohydrate-based therapeutics and vaccines. Glycan‑display platforms are technologies that present diverse sugar molecules (glycans) on surfaces or scaffolds to study their interactions with proteins, cells, or pathogens for drug and vaccine development. For instance, in October 2024, CD BioGlyco, a US-based biotechnology company, launched its Glycan Display Platform, an advanced, integrated glycan‑display technology offering multiple modalities (traditional glycan arrays, cell‑based glycan display, neoglycolipid (NGL) display, liquid glycan arrays (LiGA), glyco‑phage display, and de novo glycan display) that support a wide range of glycobiology research applications, including drug discovery and glycan‑protein interaction studies. This platform uses synthesized or natural glycans and immobilizes or presents them on carriers such as lipids, phage particles, or engineered cells, allowing researchers to explore glycan binding properties under different contexts (e.g., fluid versus immobilized, monovalent versus multivalent). Such features enable high‑throughput screening, fine‑tuned control over glycan density or presentation format, and more physiological relevance compared to traditional glycan microarrays, which usually immobilize glycans on rigid surfaces.

What Are Latest Mergers And Acquisitions In The Glycomics or Glycobiology Market?

In June 2025, Crescent BiopharmaInc Inc a US-based biotechnology company acquried GlycoMimetics for an undisclosed amount. With this acquisition, Crescent aims to strengthen its pipeline with GlycoMimetics’ portfolio of glycomimetic therapies targeting rare blood disorders and oncology indications. Crescent Biopharma Inc is a US-based biopharmaceutical company that specializes in glycobiology, particularly developing glycobiology-based therapies.

What Defines the Glycomics or Glycobiology Market?

The glycomics or glycobiology market includes revenues earned by entities by maintaining tissue structure, porosity, and integrity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glycomics or Glycobiology Market Report 2026?

The glycomics or glycobiology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glycomics or glycobiology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.